Deutetrabenazine
CAS 202841-98-6 7 FDA-DMF suppliersSmall Molecule
Overview
Deutetrabenazine is a vesicular monoamine transporter 2 (VMAT2) inhibitor used for the treatment of chorea associated with Huntington's disease and tardive dyskinesia in adults. Its chemical structure is a deuterated form of tetrabenazine, which helps improve pharmacokinetics by altering metabolic pathways.
Patent & exclusivity (US)
Per the FDA Orange Book (11 approved US products), the latest listed US patent on Deutetrabenazine expires 9 Jun 2041. Generic API sourcing typically opens up once these lapse.
Therapeutic areas
NeurologyMovement Disorders
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.